In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
How One Ovarian Cancer Survivor Turned Her Diagnosis Into a Mission to Save Lives | Heroes Highlights
As a 16-year survivor of primary peritoneal cancer who is continuously in treatment, author Jane Rubin has advice for anyone who has recently received a cancer diagnosis. “Let yourself react — it is crummy … Continued
Action Alert: Urge Congress to Reject Cuts to Vital Cancer Programs
Stop Cuts to Education, Screening & Surveillance Programs The President’s proposed budget for Fiscal Year 2026 would eliminate the CDC’s Division of Cancer Prevention and Control (DCPC). This division supports … Continued
Mercer Island Reporter Spotlights OCRA Rivkin Family SummeRun and Ovarian Cancer Research Impact
In a recent article, Mercer Island Reporter journalist Andy Nystrom looks at the history and ongoing impact of the Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, the iconic annual … Continued